1. Home
  2. HY vs PRTA Comparison

HY vs PRTA Comparison

Compare HY & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hyster-Yale Materials Handling Inc.

HY

Hyster-Yale Materials Handling Inc.

HOLD

Current Price

$31.86

Market Cap

649.1M

Sector

Industrials

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$9.61

Market Cap

526.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HY
PRTA
Founded
1991
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
Construction/Ag Equipment/Trucks
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
649.1M
526.7M
IPO Year
2012
2013

Fundamental Metrics

Financial Performance
Metric
HY
PRTA
Price
$31.86
$9.61
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$19.00
AVG Volume (30 Days)
84.1K
589.2K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
3.76%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.60
Revenue
$3,769,300,000.00
$814,000.00
Revenue This Year
$1.37
$1,111.38
Revenue Next Year
$5.29
N/A
P/E Ratio
N/A
$15.83
Revenue Growth
N/A
N/A
52 Week Low
$26.41
$6.18
52 Week High
$44.55
$11.80

Technical Indicators

Market Signals
Indicator
HY
PRTA
Relative Strength Index (RSI) 37.76 54.50
Support Level $29.88 $8.91
Resistance Level $34.57 $10.34
Average True Range (ATR) 1.78 0.49
MACD -0.55 0.11
Stochastic Oscillator 7.15 79.13

Price Performance

Historical Comparison
HY
PRTA

About HY Hyster-Yale Materials Handling Inc.

Hyster Yale Inc designs, engineers, manufactures, sells, and services a comprehensive line of lift trucks, attachments, aftermarket parts, and technology solutions marketed globally under the Hyster and Yale brand names. The company has four segments, which include three in the lift truck business as discussed below, as well as Bolzoni S.p.A. (Bolzoni). The majority of its revenue is generated from Lift Trucks. Geographically, it operates in America, EMEA, and JAPIC regions, of which maximum revenue is generated from its business in America, which includes lift truck operations in the U.S., Canada, Mexico, Brazil, and Latin America.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: